KME-2780

Overview

KME-2780 is the orally active inhibitor for IRAK1 and IRAK4 with IC 50 s of 19 nM and 0.5 nM. KME-2780 can be used for research of dysregulation of innate immune signaling and hematologic malignancies.

Application

Products | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > IRAK | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-160487
• CAS No.: 2968466-26-2
• Molecular Formula: C20H23N5
• Molecular Weight: 333.43
• Purity: 98.94%
• Storage: -20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2.5 mg/mL (7.50 mM); Clear solution
• Availability: In-stock

Source

Original product source